We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Portal Launched to Accelerate and Improve Biomedical Research Funding

By LabMedica International staff writers
Posted on 03 Apr 2016
A new website launched in collaboration with the National Institutes of Health (NIH) will provide new funding opportunities for scientific projects and present an alternative option to the traditional government grant mechanisms.

In an effort to further scientific advancement, NIH and Leidos (Reston, VA, USA), a health, national security and engineering solutions company, now provide the portal OnPAR – Online Partnership to Accelerate Research. More...
OnPAR represents a new funding paradigm that provides a second opportunity for promising unfunded NIH research proposals. Leidos developed the OnPAR processes and website and will manage the overall program.

There is currently a surplus of high-quality biomedical research applications that merit funding through alternative sources. Through the OnPAR public-private partnership, exceptional applications that were not originally funded by NIH will be matched for potential funding with a participating organization's specialized area of interest.

"OnPAR presents another avenue to fund important biomedical research," said Jim Pannucci, Leidos Director, Life Sciences, "The program will revolutionize the scientific funding environment and foster more discoveries at a faster pace to benefit and improve global health."

Research projects will be considered and funded by OnPAR funding organization members based on their specific research priority areas and requirements. For the pilot project, funding organization members include: Adenoid Cystic Carcinoma Research Foundation, Breast Cancer Research Foundation, Children's Tumor Foundation, JDRF, Melanoma Research Alliance, National Alopecia Areata Foundation, and Parent Project Muscular Distropy. These foundations were selected to span different disease areas and varied foundation sizes.

As the program progresses, OnPAR plans to increase its membership to include additional foundations, pharmaceutical companies, and other life sciences funding organizations across varied disease areas. Leidos also foresees expanding the program globally.

Related Links:

Leidos



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.